Abstract: The present invention relates to a method for measuring a biological value Vb in a liver wherein said method comprises the steps of: —a/ applying an infrared radiation having at least a first wave number range between 2800 cm?1 and 3000 cm?1 to one or more portions, pi, of a sample said liver, —b/ detecting the intensity of the radiation after it has passed through each of one or more portions, pi, and generating a signal related to the detected intensity, —c/ processing the generated signal(s) to calculated an average value va; —d/ comparing said average value Va to a standard to obtain the biological value Vb.

Abstract: The present invention relates to a method for measuring a biological value Vb in a liver wherein said method comprises the steps of: •a/ applying an infrared radiation having at least a first wave number range between 2800 cm?1 and 3000 cm?1 to one or more portions, pi, of a sample of said liver, •b/ detecting the intensity of the radiation after it has passed through each of one or more portions, pi, and generating a signal related to the detected intensity. •c/ processing the generated signal(s) to calculate an average value va; •d/ comparing said average value Va to a standard to obtain the biological value Vb.

Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.

Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.

Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.

Abstract: The present invention relates to a method for measuring a biological value Vb in a liver wherein said method comprises the steps of: a/ applying an infrared radiation having at least a first wave number range between 2800 cm?1 and 3000 cm?1 to one or more portions, pi, of a sample of said liver, b/ detecting the intensity of the radiation after it has passed through each of one or more portions, p;, and generating a signal related to the detected intensity, c/ processing the generated signal(s) to calculate an average value va; d/ comparing said average value Va to a standard to obtain the biological value Vb.

Abstract: The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.